Effects of liraglutide on cardiovascular outcomes in type 2 diabetes patients with and without baseline metformin use: Post hoc analyses of the LEADER trial

Matthew J. Crowley; Darren K. McGuire; Anastasia Stefania Alexopoulos; Thomas Jon Jensen; Søren Rasmussen; Hans A. Saevereid; Subodh Verma; John B. Buse

doi:10.2337/dc20-0437

Effects of liraglutide on cardiovascular outcomes in type 2 diabetes patients with and without baseline metformin use: Post hoc analyses of the LEADER trial

Matthew J. Crowley, Darren K. McGuire, Anastasia Stefania Alexopoulos, Thomas Jon Jensen, Søren Rasmussen, Hans A. Saevereid, Subodh Verma, John B. Buse

Research output: Contribution to journal › Letter › peer-review

20 Scopus citations

Original language	English (US)
Pages (from-to)	e108-e110
Journal	Diabetes care
Volume	43
Issue number	9
DOIs	https://doi.org/10.2337/dc20-0437
State	Published - Sep 2020

ASJC Scopus subject areas

Internal Medicine
Endocrinology, Diabetes and Metabolism
Advanced and Specialized Nursing

Access to Document

10.2337/dc20-0437

Cite this

Effects of liraglutide on cardiovascular outcomes in type 2 diabetes patients with and without baseline metformin use : Post hoc analyses of the LEADER trial. / Crowley, Matthew J.; McGuire, Darren K.; Alexopoulos, Anastasia Stefania; Jensen, Thomas Jon; Rasmussen, Søren; Saevereid, Hans A.; Verma, Subodh; Buse, John B.

In: Diabetes care, Vol. 43, No. 9, 09.2020, p. e108-e110.

Research output: Contribution to journal › Letter › peer-review

Crowley, Matthew J. ; McGuire, Darren K. ; Alexopoulos, Anastasia Stefania ; Jensen, Thomas Jon ; Rasmussen, Søren ; Saevereid, Hans A. ; Verma, Subodh ; Buse, John B. / Effects of liraglutide on cardiovascular outcomes in type 2 diabetes patients with and without baseline metformin use : Post hoc analyses of the LEADER trial. In: Diabetes care. 2020 ; Vol. 43, No. 9. pp. e108-e110.

@article{2636e65a71db4d2ab142cd6539e3383a,

title = "Effects of liraglutide on cardiovascular outcomes in type 2 diabetes patients with and without baseline metformin use: Post hoc analyses of the LEADER trial",

author = "Crowley, {Matthew J.} and McGuire, {Darren K.} and Alexopoulos, {Anastasia Stefania} and Jensen, {Thomas Jon} and S{\o}ren Rasmussen and Saevereid, {Hans A.} and Subodh Verma and Buse, {John B.}",

note = "Funding Information: The views expressed in this article are the authors{\textquoteright} and do not necessarily represent those of their employers or funding agencies. Duality of Interest. Editorial support was provided by Watermeadow Medical under a contract from Novo Nordisk. D.K.M. reports personal feesforclinicaltrialleadershipfromAstraZeneca, Sanofi, Janssen, Boehringer Ingelheim, Merck & Co., Pfizer, Lilly USA, Novo Nordisk, Lexicon, Eisai Inc., GlaxoSmithKline, and Esperion and personal fees for consultancy from AstraZeneca, Sanofi, Eli Lilly and Company, Boehringer Ingelheim, Merck & Co., Pfizer, Novo Nordisk, Dynavax, Metavant, Applied Therapeutics, and Afimmune. T.J.J. is a full-time employee of and stockholder in Novo Nordisk. S.R. is a full-time employee of and stockholder in Novo Nordisk (Significant). H.A.S. is a full-time employee of Novo Nordisk. S.V. has received grants and research support from Amgen, Abbott, Bayer, Boehringer Ingelheim, Lilly, AstraZeneca, Janssen, Sanofi, HLS Therapeutics, and Merck. J.B.B.{\textquoteright}s contracted consulting fees are paid to the University of North Carolina by Adocia, AstraZeneca, Dance Biopharm, Dexcom, Eli Lilly, Fractyl, GI Dynamics, Intarcia Therapeutics, Lexicon, MannKind, Metavention, NovaTarg, Novo Nordisk, Orexigen, PhaseBio, Sanofi, Senseonics, vTv Therapeutics, and Zafgen. He reports grant support from AstraZeneca, Eli Lilly and Company, Intarcia Therapeutics, Johnson & Johnson, Lexicon, Medtronic, Novo Nordisk, Sanofi, Theracos, Tolerion, and vTv Therapeutics; is a consultant to Cirius Therapeutics Inc., CSL Behring, Mellitus Health, Neurimmune AG, Pendulum Therapeutics, and Stability Health; and holds stock/options in Mellitus Health, Pendulum Therapeutics, PhaseBio, and Stability Health. No other potential conflicts of interest relevant to this article were reported. Author Contributions. M.J.C. helped develop the analyses, interpreted data, and wrote the manuscript. All other authors contributed to developing the analyses, interpreting data, and reviewing and editing the manuscript. S.R. was responsible for conducting the analyses. M.J.C. is the guarantor of this work and, as such, had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Funding Information: Funding. M.J.C. receives support from the Durham Center of Innovation to Accelerate Discovery and Practice Transformation (ADAPT) (Health Services Research and Development grant CIN 13-410) at the Durham Veterans Affairs Health Care System. A.-S.A. is supported by the National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases under award number T32DK007012. S.V. holds a Canada Research Chair Tier 1 Chair in Cardiovascular Surgery. J.B.B. is supported in this work from grants from the National Institutes of Health (UL1TR002489 and P30DK124723). Funding Information: M.J.C. receives support from the Durham Center of Innovation to Accelerate Discovery and Practice Transformation (ADAPT) (Health Services Research and Development grant CIN 13-410) at the Durham Veterans Affairs Health Care System. A.-S.A. is supported by the National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases under award number T32DK007012. S.V. holds a Canada Research Chair Tier 1 Chair in Cardiovascular Surgery. J.B.B. is supported in this work from grants from the National Institutes of Health (UL1TR002489 and P30DK124723). The views expressed in this article are the authors' and do not necessarily represent those of their employers or funding agencies.",

year = "2020",

month = sep,

doi = "10.2337/dc20-0437",

language = "English (US)",

volume = "43",

pages = "e108--e110",

journal = "Diabetes Care",

issn = "1935-5548",

publisher = "American Diabetes Association Inc.",

number = "9",

}

TY - JOUR

T1 - Effects of liraglutide on cardiovascular outcomes in type 2 diabetes patients with and without baseline metformin use

T2 - Post hoc analyses of the LEADER trial

AU - Crowley, Matthew J.

AU - McGuire, Darren K.

AU - Alexopoulos, Anastasia Stefania

AU - Jensen, Thomas Jon

AU - Rasmussen, Søren

AU - Saevereid, Hans A.

AU - Verma, Subodh

AU - Buse, John B.

N1 - Funding Information: The views expressed in this article are the authors’ and do not necessarily represent those of their employers or funding agencies. Duality of Interest. Editorial support was provided by Watermeadow Medical under a contract from Novo Nordisk. D.K.M. reports personal feesforclinicaltrialleadershipfromAstraZeneca, Sanofi, Janssen, Boehringer Ingelheim, Merck & Co., Pfizer, Lilly USA, Novo Nordisk, Lexicon, Eisai Inc., GlaxoSmithKline, and Esperion and personal fees for consultancy from AstraZeneca, Sanofi, Eli Lilly and Company, Boehringer Ingelheim, Merck & Co., Pfizer, Novo Nordisk, Dynavax, Metavant, Applied Therapeutics, and Afimmune. T.J.J. is a full-time employee of and stockholder in Novo Nordisk. S.R. is a full-time employee of and stockholder in Novo Nordisk (Significant). H.A.S. is a full-time employee of Novo Nordisk. S.V. has received grants and research support from Amgen, Abbott, Bayer, Boehringer Ingelheim, Lilly, AstraZeneca, Janssen, Sanofi, HLS Therapeutics, and Merck. J.B.B.’s contracted consulting fees are paid to the University of North Carolina by Adocia, AstraZeneca, Dance Biopharm, Dexcom, Eli Lilly, Fractyl, GI Dynamics, Intarcia Therapeutics, Lexicon, MannKind, Metavention, NovaTarg, Novo Nordisk, Orexigen, PhaseBio, Sanofi, Senseonics, vTv Therapeutics, and Zafgen. He reports grant support from AstraZeneca, Eli Lilly and Company, Intarcia Therapeutics, Johnson & Johnson, Lexicon, Medtronic, Novo Nordisk, Sanofi, Theracos, Tolerion, and vTv Therapeutics; is a consultant to Cirius Therapeutics Inc., CSL Behring, Mellitus Health, Neurimmune AG, Pendulum Therapeutics, and Stability Health; and holds stock/options in Mellitus Health, Pendulum Therapeutics, PhaseBio, and Stability Health. No other potential conflicts of interest relevant to this article were reported. Author Contributions. M.J.C. helped develop the analyses, interpreted data, and wrote the manuscript. All other authors contributed to developing the analyses, interpreting data, and reviewing and editing the manuscript. S.R. was responsible for conducting the analyses. M.J.C. is the guarantor of this work and, as such, had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Funding Information: Funding. M.J.C. receives support from the Durham Center of Innovation to Accelerate Discovery and Practice Transformation (ADAPT) (Health Services Research and Development grant CIN 13-410) at the Durham Veterans Affairs Health Care System. A.-S.A. is supported by the National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases under award number T32DK007012. S.V. holds a Canada Research Chair Tier 1 Chair in Cardiovascular Surgery. J.B.B. is supported in this work from grants from the National Institutes of Health (UL1TR002489 and P30DK124723). Funding Information: M.J.C. receives support from the Durham Center of Innovation to Accelerate Discovery and Practice Transformation (ADAPT) (Health Services Research and Development grant CIN 13-410) at the Durham Veterans Affairs Health Care System. A.-S.A. is supported by the National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases under award number T32DK007012. S.V. holds a Canada Research Chair Tier 1 Chair in Cardiovascular Surgery. J.B.B. is supported in this work from grants from the National Institutes of Health (UL1TR002489 and P30DK124723). The views expressed in this article are the authors' and do not necessarily represent those of their employers or funding agencies.

PY - 2020/9

Y1 - 2020/9

UR - http://www.scopus.com/inward/record.url?scp=85090093684&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85090093684&partnerID=8YFLogxK

U2 - 10.2337/dc20-0437

DO - 10.2337/dc20-0437

M3 - Letter

C2 - 32647053

AN - SCOPUS:85090093684

VL - 43

SP - e108-e110

JO - Diabetes Care

JF - Diabetes Care

SN - 1935-5548

IS - 9

ER -

Effects of liraglutide on cardiovascular outcomes in type 2 diabetes patients with and without baseline metformin use: Post hoc analyses of the LEADER trial

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this